RxDoctor Payments Data

Kylee Lienemann

Registered Nurse · Kearney, NENPI 1689244824

Payments from drug & device makers

What this record shows

18 manufacturers reported payments, led by Abbott at 33.3% of the total. 2025 is the largest year on record at $3,043, more than ten times the $5 reported in 2021.

$4,793in general payments, 2019–2025

Across 80 payments — averaging $59.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Medtronic$1K
  • Boston Scientific$1K
  • Edwards Lifesciences$83
  • Stryker$67
  • Heartflow, Inc.$64
  • plus $267 from 12 others

What the payments were for

  • Travel & lodging$2,61855%
  • Food & beverage$2,17545%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few registered nurse providers in Nebraskato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$628
Medicare patients
35
Services billed
35

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban34$28,500
EliquisApixaban21$18,653
EntrestoSacubitril/Valsartan12$7,718
BrilintaTicagrelor13$5,356
Bumetanide27$687
Potassium Chloride44$592
ClopidogrelClopidogrel Bisulfate72$501
Metoprolol Succinate54$383
Atorvastatin Calcium23$373
Amiodarone Hcl19$217
Torsemide20$203
Furosemide56$163
Metolazone19$138
Losartan Potassium14$137
Carvedilol16$81

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$21$18,65321 claims
NovartisEntresto$28$7,71812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few registered nurse providers in Nebraskaon file to place this against a meaningful peer group, so we don't.

Other registered nurse in Kearney

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →